US stock futures steady with China trade talks, Q3 earnings in focus
Twist Bioscience Corp’s stock has reached a new 52-week low, trading at $24.27, with a market capitalization of $1.47 billion. This marks a significant downturn for the company, which has seen its stock price decline by 45.18% over the past year. According to InvestingPro data, the company maintains strong liquidity with a current ratio of 3.9, despite showing high price volatility with a beta of 2.31. The drop to this 52-week low reflects ongoing challenges in the market and investor sentiment towards the company. As Twist Bioscience navigates these turbulent times, the company has maintained revenue growth of 22.72% over the last twelve months. InvestingPro analysis reveals 8 additional key insights about TWST’s financial health and future prospects, available exclusively to subscribers.
In other recent news, Twist Bioscience reported its Q3 2025 earnings, which revealed an 18% year-over-year increase in revenue, reaching $96.1 million. Despite the rise in revenue, the company posted an adjusted EBITDA loss of $8 million, showing improvement from the previous fiscal year. In terms of analyst activity, JPMorgan lowered its price target for Twist Bioscience to $25 from $33, maintaining an Underweight rating. TD Cowen also adjusted its price target to $36 from $58, while keeping a Buy rating, citing adjustments in fiscal year 2025 guidance due to changes in Next-Generation Sequencing revenue. Evercore ISI reduced its price target to $46 from $50, maintaining an Outperform rating, and noted strong performance in the next-generation sequencing segment. Furthermore, Twist Bioscience announced the appointment of Trynka Shineman Blake to its board of directors, adding her to the audit committee. Shineman Blake brings extensive leadership experience from her previous role as CEO of Vistaprint. These developments reflect ongoing changes and adjustments within Twist Bioscience as it navigates market conditions and strategic shifts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.